Evidence map›Paper›PMID 40415481›Full record

Observational studyNeurourology and urodynamics2025

Widespread Pain Moderates the Response to Centrally-Acting Therapies in an Observational Cohort of Patients With Urologic Chronic Pelvic Pain Syndrome: A MAPP Research Network Study.

Andrew Schrepf, Kenneth Locke, Robert Moldwin, David A Williams, Sara Till, John Farrar, J Richard Landis, Frank Tu, Larissa Rodriguez, Henry Lai and 11 more

2 registry-linked trialsAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurourology and urodynamics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02514265 completednot on this map

MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS)

TypeobservationalSponsorUniversity of PennsylvaniaRan2015 to 2020Enrolled640ConditionsInterstitial Cystitis, Chronic Prostatitis
NCT02898220 completednot on this map

Trans-MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol

TypeobservationalSponsorUniversity of PennsylvaniaRan2016 to 2022Enrolled72ConditionsInterstitial Cystitis, Chronic Prostatitis
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Andrew SchrepfUniversity of Michigan, Ann Arbor, Michigan, USA.ORCID http://orcid.org/0000-0003-4291-0320
Kenneth LockePerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Robert MoldwinZucker School of Medicine, Hofstra/Northwell, Hempstead, New York, USA.
David A WilliamsUniversity of Michigan, Ann Arbor, Michigan, USA.
Sara TillUniversity of Michigan, Ann Arbor, Michigan, USA.
John FarrarPerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Richard LandisPerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID http://orcid.org/0000-0001-8099-0988
Frank TuNorthShore University HealthSystem and Pritzker School of Medicine University of Chicago, Chicago, Illinois, USA.
Larissa RodriguezWeill Cornell Medicine, New York, New York, USA.
Henry LaiWashington University School of Medicine, St Louis, Missouri, USA.
Bruce NaliboffUniversity of California, Los Angeles, California, USA.
Jason KutchKeck School of Medicine, University of Southern California, Los Angeles, California, USA.
Steven E HarteUniversity of Michigan, Ann Arbor, Michigan, USA.
Richard E HarrisUniversity of California, Irvine, California, USA.
Karl J KrederUniversity of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Tracy SpitznagleWashington University School of Medicine, St Louis, Missouri, USA.
Lindsey McKernanVanderbilt University, Nashville, Tennessee, USA.
Claire YangUniversity of Washington, Seattle, Washington, USA.ORCID http://orcid.org/0000-0002-4750-6258
J Quentin ClemensUniversity of Michigan, Ann Arbor, Michigan, USA.
Chris MullinsNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
Daniel J ClauwUniversity of Michigan, Ann Arbor, Michigan, USA.

Funding

Funding for the MAPP Research Network was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) (DK82370, DK82342, DK82315, DK82344, DK82325, DK82345, DK82333, and DK82316).NIDDK NIH HHS U01 DK082315NIDDK NIH HHS U01 DK082316NIDDK NIH HHS U01 DK082325NIDDK NIH HHS U01 DK082333NIDDK NIH HHS U01 DK082342NIDDK NIH HHS U01 DK082344NIDDK NIH HHS U01 DK082345NIDDK NIH HHS U01 DK082370NIDDK NIH HHS U24 DK082316NIDDK NIH HHS U24 DK082333
6 · The paper itself

Abstract

purposeUrologic Chronic Pelvic Pain Syndrome (UCPPS) impacts millions of people in the United States but treatment options remain largely unsatisfying. A large number of neurobiological studies from the Multidisciplinary Approach to the study of chronic Pelvic Pain (MAPP) research network and others point to aberrant pain mechanisms in patients with UCPPS and widespread pain, but the clinical significance of widespread pain has been speculative. MATERIALS AND

methodsIn the current exploratory study we investigated whether pain and urologic symptoms responded to centrally-directed therapies (tricyclic antidepressants/gabapentinoids) versus peripherally-directed (pelvic floor physical therapy/hydrodistension) therapies depending on the presence or absence of widespread pain when the new treatment was initiated. RESULTS AND

conclusionsForty UCPPS patients (n = 19 widespread) underwent an evaluation of UCPPS symptoms before and after twelve weeks of either centrally-directed (n = 16) or peripherally-directed therapy. Participants were stratified post hoc into widespread (two or more non-pelvic pain sites + pelvic pain) and localized pain categories. General linear models were used to test the group X treatment interaction effect, adjusting for age, sex, and baseline outcome levels. On average, patients with widespread pain receiving centrally-directed therapies improved more than six points on the 0-28 Pelvic Pain Severity scale, while those with localized pain showed no average improvement (interaction p = 0.005). Similar effects were observed for the bladder symptom impact score (interaction p = 0.011) but not urologic symptom severity (interaction p = 0.72). While these findings are exploratory, they provide preliminary evidence for phenotype X treatment interactions in UCPPS and should be followed by confirmatory studies.

trial registrationClinicalTrials.gov Identifier: NCT02514265-MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS). CLINICALTRIALS: gov Identifier: NCT02898220-Trans-MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol.xs.

Indexed as

Chronic PainPelvic PainPhysical Therapy ModalitiesAdultFemaleGabapentinHumansMaleMiddle AgedPain MeasurementTreatment OutcomeGabapentinamitriptylinechronic paininterstitial cystitispelvic floorprostatitis

Identifiers

PMID40415481
PMCPMC12264457

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.